StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP - Free Report) from a hold rating to a buy rating in a research note issued to investors on Tuesday.
Separately, HC Wainwright reiterated a "neutral" rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.
Check Out Our Latest Stock Report on Oramed Pharmaceuticals
Oramed Pharmaceuticals Price Performance
NASDAQ:ORMP traded up $0.02 during trading hours on Tuesday, hitting $2.37. The company had a trading volume of 59,340 shares, compared to its average volume of 86,689. The stock has a 50-day moving average price of $2.39 and a 200 day moving average price of $2.39. The company has a market capitalization of $96.62 million, a PE ratio of 4.65 and a beta of 1.77. Oramed Pharmaceuticals has a 52 week low of $1.67 and a 52 week high of $3.67.
Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.21. Analysts anticipate that Oramed Pharmaceuticals will post 0.24 EPS for the current fiscal year.
Institutional Trading of Oramed Pharmaceuticals
A number of hedge funds have recently modified their holdings of ORMP. Murchinson Ltd. increased its stake in shares of Oramed Pharmaceuticals by 31.4% in the 1st quarter. Murchinson Ltd. now owns 1,379,495 shares of the biotechnology company's stock worth $4,028,000 after acquiring an additional 329,495 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Oramed Pharmaceuticals during the first quarter valued at approximately $68,000. Dimensional Fund Advisors LP increased its stake in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock valued at $81,000 after purchasing an additional 10,774 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock valued at $593,000 after purchasing an additional 108,700 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Oramed Pharmaceuticals in the 2nd quarter worth approximately $40,000. Institutional investors own 12.73% of the company's stock.
Oramed Pharmaceuticals Company Profile
(
Get Free Report)
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.
Featured Articles
Before you consider Oramed Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oramed Pharmaceuticals wasn't on the list.
While Oramed Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
